AbCellera launches $200-million equity offering on heels of strong menopause trial results
Vancouver biotech’s stock hit the highest level since early 2023 this week and is up 185% this year
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.theglobeandmail.com — the content belongs to The Globe and Mail.